| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02063581 | Healthy Volunteer | Drug: ipatasertib (Capsule)|Drug: ipatasertib (Tablet) | Genentech, Inc. | Phase 1 | 2014-02-01 | 2016-11-01 |
| NCT02536391 | Cancer | Drug: Ipatasertib (capsule)|Drug: Ipatasertib (tablet) | Genentech, Inc. | Phase 1 | 2015-10-01 | 2016-11-01 |
| NCT02162719 | Breast Neoplasms | Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo | Genentech, Inc. | Phase 2 | 2014-09-01 | 2016-11-03 |
| NCT03072238 | Metastatic Prostate Cancer | Drug: Ipatasertib|Drug: Abiraterone|Drug: Placebo | Hoffmann-La Roche | Phase 3 | 2017-06-01 | 2017-03-02 |
| NCT02390492 | Healthy Volunteer | Drug: Period 1 treatment|Drug: Period 2 treatment | Genentech, Inc. | Phase 1 | 2015-03-01 | 2016-11-01 |
| NCT02301988 | Breast Cancer | Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo | Genentech, Inc.|SOLTI Breast Cancer Research Group | Phase 2 | 2015-02-01 | 2016-11-01 |
| NCT01485861 | Prostate Cancer | Drug: Abiraterone|Drug: GDC-0980|Drug: Ipatasertib|Drug: Placebo|Drug: Prednisone|Drug: Prednisolone | Genentech, Inc. | Phase 1|Phase 2 | 2012-01-11 | 2017-03-20 |
| NCT01562275 | Neoplasms | Drug: Ipatasertib|Drug: Cobimetinib | Genentech, Inc. | Phase 1 | 2012-04-01 | 2016-02-25 |
| NCT02430363 | Glioblastoma | Drug: MK - 3475|Biological: Suppressor of the PI3K/Akt pathways | Medical Research Council|Department of Experimental Clinical Oncology, Aarhus University Hospital|NCRI Clinical Studies Groups|ECCO - the European CanCer Organisation|Merck Sharp & Dohme Corp. | Phase 1|Phase 2 | 2013-03-01 | 2016-02-23 |
